JP5395052B2 - 炎症を処置するための組成物および方法 - Google Patents
炎症を処置するための組成物および方法 Download PDFInfo
- Publication number
- JP5395052B2 JP5395052B2 JP2010501103A JP2010501103A JP5395052B2 JP 5395052 B2 JP5395052 B2 JP 5395052B2 JP 2010501103 A JP2010501103 A JP 2010501103A JP 2010501103 A JP2010501103 A JP 2010501103A JP 5395052 B2 JP5395052 B2 JP 5395052B2
- Authority
- JP
- Japan
- Prior art keywords
- tetracycline
- inflammatory
- composition
- calcium
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
Description
本願は、2007年3月23日にファイルされた米国特許出願60/896,564に関連するとともに当該米国特許出願に対して優先権を主張する。なお、当該米国特許出願は、本明細書において参考として援用される。
1)細胞成分および代謝産物(イオンチャンネル、サイトカイン、ケモカイン、受容体、細胞接着分子、先天性の結合分子(innate binding molecules)、転写因子、および一酸化窒素を含む信号伝達分子を含む)の変化;および、
2)血液循環内の炎症マーカー(白血球、赤血球の沈降速度、C反応性タンパク質、リウマチ因子、免疫グロブリンE、および、腫瘍壊死因子αとインターロイキン6とを含むサイトカイン)のレベルの上昇。
本発明は、炎症性疾患の処置のための新たなアプローチを開示している。新たな処置法は、腸内にて生じる過程が、末梢部位における炎症性疾患に非常に影響するという発見に基づいている。例えば、末梢部位におけるテトラサイクリン化合物の抗炎症作用は小腸に由来しており、このことが、これら化合物の抗炎症作用において重大な過程であることが開示されている。本発明の効果的な組成物は、テトラサイクリン化合物、および、腸から血液中へのテトラサイクリンの運搬の阻害剤である多価金属を含んでいる。以前の仮説に反して、テトラサイクリンの運搬の阻害剤は、抗炎症処置におけるテトラサイクリンの効果を増大させる。
以下に規定する用語は、本発明を示すために、請求項を含む明細書中に用いられている。
実施例中に記載された本発明の胃丸薬組成物および腸溶性丸薬組成物は、1日あたり2〜3回投与され、好ましくは、食事(朝食、昼食および夕食)と共に投与される。これらの組成物を投与してから4〜8週間後、炎症性疾患は、著しく緩和されている。
150mgのテトラサイクリン塩酸塩、300mgのCaCO3、50mgのCaCl2二水和物、100mgの酸化マグネシウム、5mgのクロスカルメロース(croscarmellose)、15mgのステアリン酸、5mgのステアリン酸マグネシウム。
80mgのドキシサイクリン塩酸塩、200mgのCaCO3、50mgのCaCl2二水和物、75mgの酸化マグネシウム、5mgのクロスカルメロース、15mgのステアリン酸、5mgのステアリン酸マグネシウム。
50mgのドキシサイクリン塩酸塩、150mgの炭酸カルシウム、50mgのCaCl2二水和物、75mgの酸化マグネシウム、5mgのクロスカルメロース、15mgのステアリン酸、5mgのステアリン酸マグネシウム。
40mgのテトラサイクリン塩酸塩、150mgの炭酸カルシウム、50mgのCaCl2二水和物、75mgの酸化マグネシウム、5mgのクロスカルメロース、15mgのステアリン酸、5mgのステアリン酸マグネシウム。
75mgのテトラサイクリン塩酸塩、200mgのCaCO3、50mgのCaCl2二水和物、50mgの塩化マグネシウム、50mgの微結晶性セルロース、4mgのクロスカルメロース、12mgのステアリン酸、4mgのステアリン酸マグネシウム。
40mgのテトラサイクリン塩酸塩、200mgのCaCO3、50mgのCaCl2二水和物、50mgの塩化マグネシウム、85mgの微結晶性セルロース、4mgのクロスカルメロース、12mgのステアリン酸、4mgのステアリン酸マグネシウム。
40mgのドキシサイクリン塩酸塩、200mgのCaCO3、50mgのCaCl2二水和物、50mgの塩化マグネシウム、85mgの微結晶性セルロース、4mgのクロスカルメロース、12mgのステアリン酸、4mgのステアリン酸マグネシウム。
30mgテトラサイクリン塩酸塩、200mgのCaCO3、50mgのCaCl2二水和物、50mgの塩化マグネシウム、50mgの微結晶性セルロース、4mgのクロスカルメロース、12mgのステアリン酸、4mgのステアリン酸マグネシウム。
Agwuh K.N., MacGowan A., Pharmacokinetics and Parmacodynamics of the Tetracyclines Including Glycylcyclines, J Antimicrob. Chemother., 58, 256-265, 2006.
Amin R.A. et al., A Novel mechanism of Action of Tetracyclines: Effects on Nitric Oxide Synthases, Proc. Natl. Acad. Sci., 93, 14014-14019, 1996.
Banack G. and Forsgren, Antibiotics and Suppression of Lymphocyte Function in Vitro, Antimicrob. Agents Chemother., 16, 554-560, 1979.
Bikowski J B, Subantimicrobial Dose of Doxycycline for Acne and Rosacea, SkinMed 2, 234-245, 2003.
Bendeck M.P. et al, Doxycycline Modulates Smooth Muscle Cell Growth, Migration, and Matrix Remodeling after Arterial Injury, Am. J. Pathol. 160, 1089-1095.
Chopra I and Roberts M, Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance, Microb. Molec. Biol. Rev. 65, 232-260, 2001.
D'Amato R.F. et al. Effect of Calcium and Magnesium on the Susceptibility of Pseudomonas Species to tetracycline, Gentamycin, Polymyxin b, and Carbenicilin, Antimicrob. Agents Chemother. 7, 596-600,1975.
Day R.O. et al., eds. Antirheumatic Therapy: Actions and Outcomes, Brikhauser Verlag, 2005, Basel, Switzerland.
DelRosso J.Q. A Status report on the Use of Subantimicrobial-Dose Doxycycline: A Review of the Biologic and Antimicrobial Effects of Tetracyclines, Cutis, 74, 118-122,2004
Deppermann et al., Influence of Ranitidine, Piperazine, and Aluminum Magnesium Hydroxide on the Bioavailability of Various Antibiotics, Antimicrob. Agents and Chemother. 33, 1901 B 1907, 1989.
Dorschner R.A. et al. The Mammalian Ionic Environment Dictates Microbial Susceptibility to Antimicrobial Defense Peptides, FASEB J., 20, 35-42, 2006.
Dreno B et al., European Recommendation on the Oral Antibiotics for Acne, Eur, J. Dermatol. 14, 391-399, 2004.
Dougherty J. M. et al, The Role of Tetracycline in Chronic Bleparitis, Invest. Ophatomol. Vis. Sci. 32, 2970-2975, 1991.
Faria A.M. and Weiner H.L., Oral Tolerance, Immunol. Rev. 206,232-259,2005.
Fordtran J.S. and Locklear T.W., Ionic Constituents and Osmolality of Gastric and Small-Intestinal Fluids after Eating, New Series, 1 1, 503- 521, 1966.
Gallin J.I et al., eds, Inflammation, Basic Principles and Clinical Correlates, 3rd ed., 1999. Lippincott Williams & Wilkins, Philadelphia.
Golub L.M. et al, Tetracyclines Inhibit Connective Tissue Brakdown by Multiple Non-Antimicrobial Mechanisms, Adv. Dent. Res. 12,12-26,1998.
Golub, L.M. et al., Can Systemic Diseases Co-induce (Not Just Exacerbate) Periodontitis? A Hypothetical "Two-hit Model, J. Dent. Res. 85, 102-105, 2006.
Guerrero-Romero F. and Rodriges-Moran M, Relationship Between Serum Magnesium Levels and C-reactive Protein concentration, Int. J. Obesity 26, 469-474, 2002.
Hansson G. Inflammation, Atherosclerosis, and Coronary Artery Disease. N. Engl. J. Med. 352, 1685-1689, 2005.
Herbert S.C. et al., Functions and Roles of the Extracellular Ca2+-sensing Receptor in the Gastrointestinal Tract, Cell calcium 35, 239-247, 2004.
Joosten L.A et al., IL-32, A Proinflammatory Cytokine in Rheumatoid Arthritis, Proc. Natl. Acad. Sci., 103, 3298-3303, 2006
Karin M. and Greten F. NF-kB: Linking Inflammation and Immunity to Cancer Development and Progression. Nature Rev. Immunol. 5, 749-759, 2005.
Krakauer T. and Buckley M. Doxycycline Is Anti-Inflammatory and Inhibits Staphylococcal Exotoxin-Induced Cytokines and Chemokines, Antimicrob. Agents Chemother. 47,3630-3633, 2003.
Kuzin I.I. et al, Tetracyclines Inhibit Activated B Cell Function, Intern. Immunol., 12, 921-931,2001.
Leyden J.J., Absorption of Minocycline Hydrochloride and Tetracycline Hydrochloride, J. Am. Acad. Dermatol, 12,308-312,1985.
Lokeshwar B. L. et al., Potential Application of Chemically Modified Non-Antimicrobial Tetracycline (CMT-3) Against Metastatic Prostate Cancer, Adv. Dent. Res. 12, 97-102, 1998.
Lucas S.M. et al. The Role of Inflammation in CNS Injury and Disease, Brit. J. Pharmacol. 147, , S232-S240.
Oracea, NDA 050805, www.accessdata.fda.gov
Oracea Prescription Information
Pelletier JP. et al. Most Recent Developments in Strategies to Reduce the Progression of Structural Changes in Osteoarthritis, Arthritis Res. Ther. 206, 8, 2006 (arthritis-research.com/content/8/2/206.
Petersen et al. In Vitro and In Vivo Antibacterial Activities of a Novel Glycylglycine, the 9-t-Butylglycylamido Derivative of Minocycline (GAR-936), Antimicrob. Agents Chemother. 43,738-74, 1999.
Pillemenr S. et al., Pilot Clinical trial of Intravenous Doxycycline Versus Placebo for Rheumatoid Arthritis, J. Rheumatol 30, 41-43, 2003.
Popovic n et al., Inhibition of Autoimmune Encephalomyelitis by a Tetracycline, Ann. Neurol., 51, 215-223, 2005.
Roberts M.C. Tetracycline Therapy: Update, Clin. Infect. Dis., 36, 462-467, 2003.
Sapadin A N and Fleischmajer R, Tetracyclines: Nonantibiotic Properties and their Clinical Implications, J. Am. Acad. Dermatol., 54, 258-265, 2006.
Skinner M. at al., Tetracycline in the Treatment of Rheumatoid Arthritis, Arthritis Rheum. 14, 727-732,1971.
Sompolinsky D. and Samra Z., Influence of Magnesium and Manganese on Some Biological and Physical Properties of Tetracycline, J. Bacteriol. 110, 468-476, 1972.
St.Clair E. W. et al., The Effects of Intravenous Doxycycline Therapy for Rheumatoid Arthritis, Arthritis. Rheum, 44, 1043-1047, 2001.
Stone M. et al, Should Tetracycline Treatment Be Used More Extensively for Rheumatoid Arthritis? Metaanalysis Demonstrate Clinical Benefit with Reduction in Disease Activity, J. Rheumatol, 30, 2112- 2022, 2003.
Toussirot E. A., Oral Tolerance in the Treatment of Rheumatoid Arthritis, Drug Inflamm. Allergy, 1, 45-52, 2002.
Vibramycin, http://dailvmed.nlm.nih.gov
Webster G.F. et al., Suppression of Polymorphonuclear Leukocyte Chemotactic Factor production in Propionobacterium acnes by Subminimal Inhibitory Concentrations of Tetracycline, Ampicilin, Minocycline, and Erythromycin, Antimicrob. Agents Chemother. 21, 770-772, 1982.
Weinberg M.A., New Applications of Doxycycline Hyclate in Medicine and Dentistry, US Pharmacist, 29, 04, 2004, http://uspharmacist.com.
Welling P.G., Koch P.A, Curtis CL and Craig W.A., Bioavailability of Tetracycline and Doxycycline in fasted and Nonfasted Subjects, Antimicrob. Agents Chemother., 11, 462-469, 1976.
Wellen K.E. and Hotamisigil G. Inflammation, Stress, and Diabetes, J. Clin. Invest. 115, 1111-1119, 2005.
Worbs T et al, Oral Tolerance Originates in the Intestinal Immune System and Relies on the Antigen Carriage by Dendritic Cells, J. Exp. Med. 203, 519-527, 2006.
Wyeth Pharmaceuticals, UK, Minocin MR, SPC; 2005, http://emc.medicines.org.uk
Claims (4)
- 1つ以上の天然テトラサイクリン化合物と、テトラサイクリン化合物の吸収を阻害する1つ以上の効果的なテトラサイクリン吸収阻害剤とから、本質的に成り、
1つ以上の薬学的に活性な添加物と、1つ以上の賦形剤とを任意で含み、
上記テトラサイクリン吸収阻害剤は、1つ以上の多価金属を含み、当該多価金属は、塩、または、胃内または腸内で塩に変換され得る化合物の形態であり、
上記天然テトラサイクリン化合物を、1服あたり、略0.02mmole〜略4mmole含み、
上記多価金属のモル比が、1moleのテトラサイクリン化合物に対して、略10moleよりも高く、75mole未満であり、
上記多価金属は、カルシウム、マグネシウム、無毒な量の鉄もしくは亜鉛、または、これらの組み合わせであり、
経口投与するための抗炎症剤。 - 上記多価金属のモル比が、略15mole〜略40moleである、請求項1に記載の抗炎症剤。
- 上記薬学的に活性な添加物は、好ましくは抗生物質、ステロイド抗炎症化合物、非ステロイド抗炎症化合物、ホルモン、ビタミン、メントールおよびこれらの組み合わせから選択される請求項1に記載の抗炎症剤。
- 胃組成物または腸溶性組成物として製剤されている請求項1に記載の抗炎症剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89656407P | 2007-03-23 | 2007-03-23 | |
US60/896,564 | 2007-03-23 | ||
PCT/US2008/057646 WO2008118744A1 (en) | 2007-03-23 | 2008-03-20 | Anti-inflammatory compositions comprising tetracyclines and use thereof in therapy |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010522240A JP2010522240A (ja) | 2010-07-01 |
JP2010522240A5 JP2010522240A5 (ja) | 2011-03-31 |
JP5395052B2 true JP5395052B2 (ja) | 2014-01-22 |
Family
ID=39651298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010501103A Expired - Fee Related JP5395052B2 (ja) | 2007-03-23 | 2008-03-20 | 炎症を処置するための組成物および方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20080233206A1 (ja) |
EP (1) | EP2125018A1 (ja) |
JP (1) | JP5395052B2 (ja) |
KR (2) | KR20130137696A (ja) |
CN (2) | CN102688492A (ja) |
AP (1) | AP2657A (ja) |
AU (1) | AU2008231033B2 (ja) |
EA (1) | EA016206B1 (ja) |
WO (1) | WO2008118744A1 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103040773A (zh) | 2003-07-25 | 2013-04-17 | 沃纳奇尔科特有限责任公司 | 多西环素金属络合物固体剂型 |
ES2588584T3 (es) * | 2005-01-21 | 2016-11-03 | Warner Chilcott Company, Llc | Un complejo metálico de tetraciclina en una forma de dosificación sólida |
RU2647972C2 (ru) * | 2010-05-12 | 2018-03-21 | Ремпекс Фармацеутикалс, Инк. | Тетрациклиновая композиция |
US9119793B1 (en) | 2011-06-28 | 2015-09-01 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for doxycycline |
CN103536607A (zh) * | 2012-07-10 | 2014-01-29 | 邵金辉 | 土霉素,普罗帕酮和安乃近的抗肿瘤作用 |
PT106679B (pt) * | 2012-11-27 | 2015-03-25 | Hovione Farmaciencia Sa | Formulações tópicas de tetraciclinas, sua preparação e usos |
US10842802B2 (en) | 2013-03-15 | 2020-11-24 | Medicis Pharmaceutical Corporation | Controlled release pharmaceutical dosage forms |
ITMI20132066A1 (it) * | 2013-12-11 | 2015-06-12 | Farmatron Ltd | Sistemi terapeutici a rilascio modificato per la somministrazione orale di mentolo nel trattamento delle malattie intestinali |
WO2015153864A2 (en) * | 2014-04-02 | 2015-10-08 | Hopkins Patricia T | Methods for treating inflammatory conditions |
CN103933539B (zh) * | 2014-04-16 | 2017-01-11 | 西北农林科技大学 | 一种含有四环素的药物组合物及其应用 |
TW201705962A (zh) | 2015-03-23 | 2017-02-16 | 生物製藥X公司 | 皮膚用四環素醫藥組成物 |
CN105998037A (zh) * | 2016-06-16 | 2016-10-12 | 汕头大学 | 多西环素在制备治疗或预防衰老性疾病的药物中的用途 |
CO2017001953A1 (es) * | 2017-02-27 | 2018-08-31 | Corporacion Univ Lasallista | Método de encapsulación de tetraciclinas |
JP7506679B2 (ja) * | 2018-10-29 | 2024-06-26 | フラウンホーファー-ゲゼルシャフト・ツール・フェルデルング・デル・アンゲヴァンテン・フォルシュング・アインゲトラーゲネル・フェライン | 持続性活性を有するテトラサイクリン複合体 |
CN110169973A (zh) * | 2019-06-11 | 2019-08-27 | 贾树森 | 一种用于颈椎康复的外用药物组合物 |
CN111870607A (zh) * | 2020-07-09 | 2020-11-03 | 温州医科大学 | 盐酸米诺环素作为制备治疗自身免疫性葡萄膜炎药物的应用及其治疗方法 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2736725A (en) * | 1954-03-11 | 1956-02-28 | American Cyanamid Co | Complexes of tetracycline antibiotics and preparation of same |
US2766124A (en) * | 1954-05-25 | 1956-10-09 | American Cyanamid Co | Antibiotic-containing ice composition |
US2806789A (en) * | 1954-09-10 | 1957-09-17 | American Cyanamid Co | Enhancement of therapeutic efficacy of antibiotics |
GB901209A (en) * | 1957-10-23 | 1962-07-18 | Pfizer & Co C | 6-deoxytetracyclines and compositions containing same |
GB901107A (en) * | 1959-06-29 | 1962-07-11 | Pfizer | Therapeutic composition and method of preparing same |
GB894619A (en) * | 1959-09-11 | 1962-04-26 | Pfizer & Co C | Stabilized liquid preparations comprising tetracycline antibiotics |
FR1430859A (ja) * | 1960-05-23 | 1966-05-25 | ||
US3275513A (en) * | 1963-05-29 | 1966-09-27 | American Cyanamid Co | Stable calcium tetracycline compositions |
US4061676A (en) * | 1970-07-03 | 1977-12-06 | Ivan Villax | Recovery of doxycycline and products thereof |
US3957980A (en) * | 1972-10-26 | 1976-05-18 | Pfizer Inc. | Doxycycline parenteral compositions |
US4060605A (en) * | 1973-09-28 | 1977-11-29 | Ankerfarm, S.P.A. | Water-soluble derivative of 6-deoxy-tetracyclines |
DK153784C (da) * | 1973-09-28 | 1989-01-23 | Pfizer | Analogifremgangsmaade til fremstilling af 2-n-(methioninomethyl)doxycyclin eller salte deraf |
US4150111A (en) * | 1974-05-28 | 1979-04-17 | Allister Warren | Enteric coated magnesium chloride |
JPS51107134A (en) * | 1975-03-17 | 1976-09-22 | Asahi Optical Co Ltd | Shotenmenkenshutsusochi |
US4081527A (en) * | 1976-12-07 | 1978-03-28 | Pfizer Inc. | Chlortetracycline compositions |
US4126680A (en) * | 1977-04-27 | 1978-11-21 | Pfizer Inc. | Tetracycline antibiotic compositions |
US4837030A (en) * | 1987-10-06 | 1989-06-06 | American Cyanamid Company | Novel controlled release formulations of tetracycline compounds |
EP0327295A3 (en) * | 1988-02-01 | 1989-09-06 | F.H. FAULDING & CO. LTD. | Tetracycline dosage form |
US5250442A (en) * | 1993-04-08 | 1993-10-05 | Orestes Cabezas | Method of treating rheumatoid arthritis using tetracycline |
US5538954A (en) * | 1994-06-24 | 1996-07-23 | A/S Dumex (Dumex Ltd.) | Salts of tetracyclines |
US5614206A (en) * | 1995-03-07 | 1997-03-25 | Wright Medical Technology, Inc. | Controlled dissolution pellet containing calcium sulfate |
US6010722A (en) * | 1995-06-13 | 2000-01-04 | Nippon Meat Packers, Inc. | Oral remedy for rheumatoid arthritis and functional food |
US5789395A (en) * | 1996-08-30 | 1998-08-04 | The Research Foundation Of State University Of New York | Method of using tetracycline compounds for inhibition of endogenous nitric oxide production |
US5968896A (en) * | 1998-01-16 | 1999-10-19 | Beth Israel Deaconess Medical Center | Nutritional supplement for preoperative feeding |
CA2360938C (en) * | 1999-02-02 | 2008-01-08 | Warren Oliver Haggard | Controlled release composite |
US6765000B2 (en) * | 1999-03-17 | 2004-07-20 | Bonner Jr Ernest L | Treatment for reactive arthritis or bursitis |
US7884090B2 (en) * | 1999-03-17 | 2011-02-08 | Ernest L. Bonner, Jr. | Compositions and methods for the treatment of arthritis |
US6946118B1 (en) * | 1999-09-14 | 2005-09-20 | Orapharma, Inc. | Formulations for treating or preventing mucositis |
US6638532B2 (en) * | 2000-02-24 | 2003-10-28 | Advancis Pharmaceutical Corp. | Tetracycline—doxycycline antibiotic composition |
US6887492B2 (en) * | 2000-12-14 | 2005-05-03 | Leiner Health Services Corp. | Magnesium plus interactive agent delivery |
US7211267B2 (en) * | 2001-04-05 | 2007-05-01 | Collagenex Pharmaceuticals, Inc. | Methods of treating acne |
ATE330615T1 (de) * | 2001-04-05 | 2006-07-15 | Collagenex Pharm Inc | Doxycyclin zur behandlung von akne |
WO2002089743A2 (en) * | 2001-05-09 | 2002-11-14 | The Regents Of The University Of Michigan | Use of compositions for treating rosacea |
US20060194773A1 (en) * | 2001-07-13 | 2006-08-31 | Paratek Pharmaceuticals, Inc. | Tetracyline compounds having target therapeutic activities |
US7122578B2 (en) * | 2001-09-11 | 2006-10-17 | Alain Martin | Method and composition for treating mammalian diseases and injuries which cause pain, erythema, swelling, crusting, ischemia scarring and excess white blood cell infiltration |
NO315915B1 (no) * | 2002-02-25 | 2003-11-10 | Sintef Elektronikk Og Kybernet | Fj¶rvekt |
JP2005533766A (ja) * | 2002-05-20 | 2005-11-10 | コッラジェネックス ファーマシューチカルス インコーポレイテッド | アレルギー反応の治療方法 |
CN103040773A (zh) * | 2003-07-25 | 2013-04-17 | 沃纳奇尔科特有限责任公司 | 多西环素金属络合物固体剂型 |
EP2949644A3 (en) * | 2004-10-25 | 2016-04-20 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
ES2588584T3 (es) * | 2005-01-21 | 2016-11-03 | Warner Chilcott Company, Llc | Un complejo metálico de tetraciclina en una forma de dosificación sólida |
US7919483B2 (en) * | 2005-06-24 | 2011-04-05 | Medicis Pharmaceutical Corporation | Method for the treatment of acne |
-
2008
- 2008-03-20 CN CN2012101925621A patent/CN102688492A/zh active Pending
- 2008-03-20 JP JP2010501103A patent/JP5395052B2/ja not_active Expired - Fee Related
- 2008-03-20 AP AP2009004979A patent/AP2657A/xx active
- 2008-03-20 EP EP08732557A patent/EP2125018A1/en not_active Ceased
- 2008-03-20 CN CN200880016401A patent/CN101678108A/zh active Pending
- 2008-03-20 WO PCT/US2008/057646 patent/WO2008118744A1/en active Application Filing
- 2008-03-20 EA EA200901289A patent/EA016206B1/ru not_active IP Right Cessation
- 2008-03-20 KR KR1020137028763A patent/KR20130137696A/ko active IP Right Grant
- 2008-03-20 AU AU2008231033A patent/AU2008231033B2/en not_active Ceased
- 2008-03-20 KR KR1020097021550A patent/KR20090122994A/ko not_active Application Discontinuation
- 2008-03-21 US US12/053,020 patent/US20080233206A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN102688492A (zh) | 2012-09-26 |
KR20130137696A (ko) | 2013-12-17 |
EP2125018A1 (en) | 2009-12-02 |
CN101678108A (zh) | 2010-03-24 |
AP2657A (en) | 2013-05-07 |
EA200901289A1 (ru) | 2010-02-26 |
JP2010522240A (ja) | 2010-07-01 |
AU2008231033A1 (en) | 2008-10-02 |
AU2008231033B2 (en) | 2012-08-30 |
US20080233206A1 (en) | 2008-09-25 |
KR20090122994A (ko) | 2009-12-01 |
AP2009004979A0 (en) | 2009-10-31 |
WO2008118744A1 (en) | 2008-10-02 |
EA016206B1 (ru) | 2012-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5395052B2 (ja) | 炎症を処置するための組成物および方法 | |
US6346519B1 (en) | Method and composition for treating arthritis | |
JP3806427B2 (ja) | 新規鎮痛剤 | |
RU2541092C2 (ru) | Бисглицинат-хелат железа для использования в пероральном лечении анемии у пациентов с целиакией | |
WO2018045244A1 (en) | Magnesium biotinate compositions and methods of use | |
CA2476939A1 (en) | Pharmaceutical combinations of cox-2 inhibitors and opiates | |
AU2011264808B2 (en) | Oral iron deficiency therapy | |
RU2437653C1 (ru) | Способ лечения и профилактики желудочно-кишечных болезней новорожденных телят | |
JPH06503806A (ja) | 胃腸疾病を処置するための5―ジフルオロメトキシ―2―[(3,4―ジメトキシ―2―ピリジル)メチルスルフィニル]ベンズイミダゾール及び抗ヘリコバクター剤含有医薬組成物 | |
US20160250253A1 (en) | Strontium-containing complexes for treating gastroesophageal reflux and barrett's esophagus | |
Johnson | Oral elemental diet: a new bowel preparation | |
JP2017101081A (ja) | 経口b12治療 | |
CN112638378A (zh) | 用于根除幽门螺杆菌的组合物 | |
Chomczynski et al. | Compositions and methods for anti-inflammatory treatments | |
AU2012230089B2 (en) | Anti-inflammatory compositions comprising tetracyclines and use thereof in therapy | |
CA2754281C (en) | Antiviral combination of zinc and trimethoprim | |
JP7332489B2 (ja) | ホスホジエステラーゼ3阻害用組成物及び血小板凝集抑制用組成物 | |
JP4384435B2 (ja) | くしゃみ抑制組成物 | |
CN114585380A (zh) | 胃肠健康组合物 | |
US20050227949A1 (en) | Compositions and methods for treatment of viral and bacterial infections | |
WO2006043336A1 (ja) | 胃粘膜疾患の治療又は予防のための組成物 | |
JP2586542B2 (ja) | 牛の第四胃変位の治療剤 | |
JP2006117569A (ja) | ステロイド依存性あるいはステロイド抵抗性潰瘍性大腸炎治療薬 | |
JP3486755B2 (ja) | 高燐血症予防・治療剤 | |
JP2002121139A (ja) | カルシウム依存性ドパミン機能亢進阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110207 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110207 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130108 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130307 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130402 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130802 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20130802 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130805 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130827 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131008 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131017 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |